Vascepa's Common Side Effects
Vascepa (icosapent ethyl), a purified EPA omega-3 fatty acid, primarily causes mild gastrointestinal issues like joint pain (3.4% vs 2.8% placebo), constipation (2.3% vs 1.9%), and edema (2.7% vs 2.1%). Serious risks include atrial fibrillation (3.1% vs 2.1%) and bleeding (2.7% vs 2.1%), often in patients on anticoagulants.[1][2]
How It Differs from Statins
Statins like atorvastatin or rosuvastatin, standard for high triglycerides, frequently cause muscle pain (5-10%), liver enzyme elevations (1-3%), and rare rhabdomyolysis. Vascepa shows no myopathy or liver toxicity signals, making it a statin add-on for patients intolerant to these effects. REDUCE-IT trial data confirmed Vascepa's CV benefits without amplifying statin-related muscle risks.[1][3]
Comparison to Fibrates
Fibrates (e.g., fenofibrate) reduce triglycerides but raise LDL-C by 10-20% and creatinine levels, with higher GI upset and gallstone risks. Vascepa lowers triglycerides 20-30% without LDL-C increase or renal effects, and REDUCE-IT showed superior CV outcomes (25% risk reduction) versus fibrates' mixed data.[1][4]
Edge Cases: Patients on Anticoagulants or Diabetes
Vascepa slightly elevates bleeding risk with antiplatelets/anticoagulants (use caution), unlike statins which have minimal interaction. In diabetics (common in CV trials), it avoids fibrate-like renal strain but monitor AFib, as rates doubled in REDUCE-IT subgroups.[2][3]
Long-Term Safety Data
Over 5+ years in REDUCE-IT, Vascepa's profile remained consistent, with no new signals versus shorter-term statin/fibrate trials. No cancer or cognitive risks seen, contrasting rare statin associations.[1][3]
[1]: FDA Vascepa Label
[2]: REDUCE-IT Trial (NEJM 2019)
[3]: Amarin REDUCE-IT Post-Hoc Analyses
[4]: DrugPatentWatch.com - Vascepa Competitors